Apoptosis is a form of programmed cell death, it removes cells which are no longer needed or are dangerous and is key for development, immune system function and tumour suppression. The BCL‑2 family members, BAX and BAK, are essential mediators of apoptosis, as they execute and regulate the intrinsic apoptotic pathway upon a death stimulus1. It has previously been shown that voltage dependent anion channel 2 (VDAC2) binds to BAK and BAX at the mitochondrial outer membrane (MOM) and regulates their apoptotic function2,3. In healthy cells, BAX and BAK are found to form distinct complexes with VDAC2 at the mitochondria that dissociate upon an apoptotic stimulus4. The apoptosis inhibitor WEHI-9625 has been reported to bind VDAC2 and selectively block apoptosis driven by murine BAK (mBAK)5, also highlight the interaction between BAK and VDAC2 as a promising drug target to manipulate apoptosis.
This project aims to investigate the role of these complexes in BAX/BAK-mediated apoptosis and provide structural information regarding the BAK: VDAC2 and BAX: VDAC2 complexes. We use X-ray crystallography and Cryo-EM techniques to study structures of these protein complexes, SPR and thermal shift assays to understand interactions between the small molecule WEHI-9625 and VDAC2. These studies will provide us further insights into BAX/BAK-mediated apoptotic pathways and how can we manipulate apoptosis via the protein VDAC2. We have purified recombinant VDAC2 by refolding and did some binding assays with the small molecule WEHI-9625. In the meantime, we are in the process of purifying the BAK: VDAC2 complex for later Cryo-EM studies.